Navigation Links
Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
Date:6/12/2013

NORCROSS, Ga., June 12, 2013 /PRNewswire-USNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that preclinical studies have shown that combining the galectin inhibitor GR-MD-02 with monoclonal antibodies that function as immune checkpoint blockade inhibitors enhance shrinkage of prostate and breast cancer tumors. These data were generated by the laboratory of Dr. William Redmond of the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute (EACRI) at Providence Cancer Center (Portland, OR), an expert in tumor immunology and part of a comprehensive pre-clinical and clinical program in cancer immunotherapy. The addition of GR-MD-02, a drug that inhibits galectin proteins, was found to increase tumor shrinkage and enhance survival in immune competent mice with prostate and breast cancers when combined with one of the immune checkpoint blockade inhibitors, anti-CTLA-4 or anti-PD-1.

"Immunotherapy with checkpoint blockade inhibitors, such as anti-CTLA-4 monoclonal antibodies (marketed as YERVOY™ by Bristol-Myers Squibb (BMS)) and anti-PD-1 monoclonal antibodies (in development at BMS and Merck), is an extremely exciting area for advancing human cancer immunotherapy," said Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. "However, these agents are currently only effective in a limited percentage of patients. The ability of GR-MD-02 to increase the effectiveness of these important drugs is a potentially important approach to enhance cancer immunotherapy."

"The findings of these experiments show that GR-MD-02 had a robust effect on augmenting the immune response and tum
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
6. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
8. ClearCanvas Platform Powers Tumor Imaging Metrics Core Measurements
9. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
10. Lo screening trial sul cancro al seno conclude che lutilizzo della mammografia 3D in combinazione con un esame del seno 2D rileva un numero di tumori significativamente maggiore rispetto al solo esame del seno 2D
11. La nuova tecnologia Elekta per la radioterapia oncologica ridefinirà il futuro della lotta contro i tumori
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... BARCELONA , Spanien, September 2, ... -- Das auf dem ESC-Kongress 2014 ... die Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten ...    Die Daten ... eingetragenen Patienten, einer innovativen und unabhängigen ...
(Date:9/2/2014)... Sept. 2, 2014 Particle Sciences, the leading ... investment in development and manufacturing capabilities with the addition ... Mueller , Particle Sciences, Associate Director Clinical Production, "The ... clean room square footage, equipment and staff across the ... company now has over 6000ft 2 of operating ...
(Date:9/2/2014)... Sept. 2, 2014  Edison Nation Medical, the ... with the American Association for Respiratory Care ( ... care specialists. Edison Nation Medical, which brings 12+ ... to commercialize their innovation ideas, will work with ... more than 50,000 respiratory therapists in bringing their ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3
... , , , , , LOVELAND, Colo. , Feb. 8 Heska Corporation (Nasdaq: ... , , What: Heska Corporation Invites ... Year-End 2009 Earnings Conference Call on the Web, , ... , Where: www.heska.com (click on the Q4 and Year-End 2009 Earnings ...
... DIEGO , Feb. 8 PatientSafe Solutions, Inc., ... that help to eliminate hospital-based medical errors, announced today that ... financing. The financing was led by TPG Biotech, the leading ... TPG Capital. Co-leads for this financing include Camden Partners and ...
Cached Medicine Technology:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2009 Earnings Conference Call Webcast 2PatientSafe Solutions, Inc. Closes $30 Million Financing 2PatientSafe Solutions, Inc. Closes $30 Million Financing 3
(Date:9/2/2014)... News) -- A leading group of oncologists has released ... of advanced breast cancer. HER2-negative breast tumors ... the HER2 protein, the American Society of Clinical Oncology ... Almost 80 percent of women with advanced breast cancer ... this guideline, our aim is to improve both the ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
(Date:9/2/2014)... less intensive (and expensive) practice patterns appear to consistently ... unnecessary and excessive medical care, according to a new ... concern about the costs and harms of medical care ... the provision of unnecessary care," said lead author Brenda ... Institute for Health Policy & Clinical Practice. , ...
(Date:9/2/2014)... 02, 2014 Anti-aging is proving ... services such as anti-wrinkle treatments and products, hair ... and breast augmentation becoming much sought after worldwide. ... market intelligence firm Transparency Market Research, the global ... grow to USD 191.7 billion by 2019, from ...
(Date:9/2/2014)... When weather conditions are right, tornadoes can occur anywhere and ... of destruction. In fact, the United States leads the world ... year. Rainbow International offers the following safety tips on how ... , Select a safe place such as a basement, ... windows to stay during the storm. If a tornado is ...
Breaking Medicine News(10 mins):Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2
... 10 GeneGo, Inc., a leading,provider of software and ... announced that A*STAR,s Singapore Immunology Network (SIgN) has become ... have access,to GeneGo,s MetaCore, training and advanced support. ... SIgN researchers. , ...
... brings together in one resource the necessary information to make ... any time of year , , ... pediatrician to identifying the city,s best otolaryngologist (and figuring out ... a daunting task, especially if you,re not an MD, a ...
... to provide national contracting portfolio, e-commerce exchange and clinical services ... ... announced today that Jordan Health Systems in Plymouth, Massachusetts has ... supply chain services to help manage its approximate $35 ...
... , TUCSON, Ariz., Dec. 10 ... ) today announced that its Board of Directors has adopted ... will receive rights to purchase shares of the Company,s Series ... "In this period of unprecedented market volatility where ...
... December 10 ICON plc (NASDAQ:, ... development,services to the pharmaceutical, biotechnology and medical ... division has launched a new cardiac,echocardiography analysis ... (ECHO) images to be viewed, measured and ...
... over two and a half times more likely to ... a motor vehicle crash compared with normal weight children, ... Bloomberg School of Public Health,s Center for Injury Research ... likely to experience injury to any body part following ...
Cached Medicine News:Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Vitals Launches Free eBook to Help Consumers Find 'Dr. Right' 2Health News:Jordan Health Systems Selects Broadlane to Provide Comprehensive Supply Chain Services 2Health News:Jordan Health Systems Selects Broadlane to Provide Comprehensive Supply Chain Services 3Health News:Providence Service Corporation Adopts Shareholder Rights Plan 2Health News:Providence Service Corporation Adopts Shareholder Rights Plan 3Health News:ICON Medical Imaging Launches New Cardiac Echocardiography Analysis Software 2Health News:Overweight children at increased risk of arm and leg injuries following motor vehicle crash 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: